Phase I BLASST-3 Trial

NCT04972253 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Low Accrual

Conditions

Bladder Transitional Cell Carcinoma
Bladder Cancer
Fibroblast Growth Factor Receptor

Interventions

DRUG: Infigratinib

Sponsor

Guru P. Sonpavde

Collaborators

[object Object]